SS-31 (Elamipretide): Evidence, Mechanism & FDA Status

Elamipretide (SS-31, MTP-131, formerly Bendavia; brand Forzinity) is a synthetic, water-soluble, mitochondria-targeting tetrapeptide that concentrates in the inner mitochondrial membrane, binds the phospholipid cardiolipin, and supports bioenergetic function.1 After two decades of development by Stealth BioTherapeutics its clinical record is decidedly mixed, and this monograph separates what is proven from what is hyped.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. Outside Barth syndrome, elamipretide is investigational; non-Barth 'research-use' SS-31 is unapproved, non-pharmaceutical-grade material. Dosing figures are reported strictly as seen in the FDA label and trial literature for completeness — not as recommendations. Consult a licensed clinician before any health decision.

What is SS-31 and how does it work?

Elamipretide is a non-glycosylated synthetic tetrapeptide, sequence D-Arg-Dmt-Lys-Phe-NH2 (CAS 736992-21-5, molecular formula C32H49N9O5, MW about 640 Da), belonging to the Szeto-Schiller 'aromatic-cationic' peptide class originally discovered during opioid-peptide synthesis.13 Its alternating cationic (D-Arg, Lys) and aromatic (Dmt, Phe) residues give it amphipathic character and self-directed mitochondrial uptake that is independent of membrane potential; the Dmt residue resists oxidation and the D-Arg confers protease resistance.1

Unlike most drugs, elamipretide does not act on a cell-surface receptor. It crosses the plasma membrane, concentrates several-thousand-fold in mitochondria, and localizes to the inner mitochondrial membrane where it binds cardiolipin — the signature dimeric phospholipid that scaffolds cristae curvature and clusters the oxidative-phosphorylation complexes into respiratory supercomplexes.1 The reported downstream consequences are coherent: it reduces cardiolipin peroxidation to preserve cristae integrity, stabilizes respiratory supercomplexes and improves activity of electron-transport-chain complexes I, III and IV to restore ATP synthesis, and lowers electron leak and reactive-oxygen-species production while inhibiting mitochondrial permeability-transition-pore opening.12 The FDA label frames the mechanism simply as a 'mitochondrial cardiolipin binder.'4 This is a genuine root-cause, organelle-level intervention — but mechanistic elegance has repeatedly failed to translate to primary clinical endpoints, which is precisely why evidence grading matters here.

Pharmacokinetically, the label reports rapid subcutaneous absorption (Tmax 0.5-1 h), absolute bioavailability of about 92%, volume of distribution about 0.5 L/kg, and plasma protein binding about 39%.4 It is metabolized by sequential C-terminal degradation to inactive tripeptide and dipeptide metabolites, with roughly 100% of the dose recovered in urine within 48 hours and minimal accumulation on once-daily dosing. Exposure rises substantially with renal impairment (AUC up about 125% in severe impairment), which drives the renal dose reduction.4

What is the evidence by indication?

Elamipretide has a real human RCT base — several large, double-blind, placebo-controlled trials — which is unusual for a peptide marketed in longevity circles. The problem is that the trials were mostly negative on their primary endpoints. The trial registrations are publicly searchable on ClinicalTrials.gov, and the table below grades each indication honestly.

Barth syndrome (Grade A, narrow claim). Barth is an X-linked recessive mitochondrial cardioskeletal disease affecting roughly 150 people in the US, predominantly males.6 TAZPOWER (NCT03098797) was a 28-week randomized, double-blind, placebo-controlled crossover trial in just 12 patients; the randomized phase showed no significant effect on the primary endpoints (6-minute walk test and fatigue).13 However, the open-label extension showed sustained gains — knee-extensor strength improved by more than 45%, reaching a median change of +63 newtons at Week 168 — and a natural-history comparison found a 6MWT group difference of +79.7 m (P=0.0004) at week 64.414 On this basis the FDA granted accelerated approval on September 19, 2025, making elamipretide the first approved Barth therapy.4 The caveat is real: approval rests on an intermediate endpoint in a tiny cohort with a negative pivotal randomized phase, so this is Grade A for the narrow approved claim, not a robust large-RCT base.

The four large negative trials (Grade B). MMPOWER-3 randomized 218 genetically confirmed primary-mitochondrial-myopathy patients to 40 mg/day or placebo and did not meet its co-primary endpoints, though a prespecified nuclear-DNA-defect subgroup and a post-hoc mtDNA-replisome cohort showed hypothesis-generating benefit, motivating the follow-up NuPOWER trial.79 PROGRESS-HF randomized 71 HFrEF patients and found no significant change in left-ventricular end-systolic volume.10 EMBRACE-STEMI did not reduce myocardial infarct size in first anterior STEMI.1 ReCLAIM-2 (NCT03891875) enrolled 176 dry-AMD patients and missed its co-primary endpoints, but prespecified analyses showed attenuated ellipsoid-zone degradation (p<0.01) and a categorical visual-acuity gain, prompting the phase-3 ReNEW program.1115 Across all four, the safety profile was consistently benign.

What doses appear in the literature?

Reported strictly as information, not a protocol. The approved Forzinity dose for Barth syndrome (>=30 kg) is 40 mg subcutaneously once daily, reduced to 20 mg once daily in adults with severe renal impairment (eGFR <30 mL/min, not on dialysis).4 The formulation is a ready-to-use sterile aqueous solution in which each 0.5 mL delivers 40 mg of elamipretide, preserved with benzyl alcohol (20 mg/mL).4 Investigational trials used the same 40 mg subcutaneous once-daily dose in mitochondrial myopathy (MMPOWER-3) and dry AMD (ReCLAIM-2), while PROGRESS-HF tested both 4 mg and 40 mg.71110 'Research-use-only' SS-31 vials sold by peptide vendors are unapproved, non-pharmaceutical-grade products carrying no validated dosing, purity or sterility assurance; the FDA-approved route is the only one with established pharmacokinetics and safety, and no legitimate clinical protocol exists for non-Barth use.18

How safe is SS-31?

In the FDA placebo-controlled Barth data, injection-site reactions were very common — any local reaction in 100% of treated patients (versus 67% placebo), with erythema 100%, pain 75%, induration 67% and pruritus 67%.4 Eosinophil counts peaked roughly 90 days after first exposure and normalized over 6 to 12 months. Across the broader program other effects were mild — headache, dizziness, nausea, abdominal pain, fatigue — with no clinically significant changes in vitals, labs, exam or ECG even in the 168-week extension.1 Warnings include hypersensitivity reactions (rash, eczematous dermatitis, cough) that may occur minutes to months after initiation, and benzyl-alcohol toxicity — the excipient is associated with fatal 'gasping syndrome' in neonates, so the drug is not for neonatal use.4 The only contraindication is serious hypersensitivity to elamipretide or any excipient. Unlike pro-angiogenic peptides, elamipretide is not known to be angiogenic or tumor-promoting; no tumor-promotion signal has been reported in its trials, though long-term oncologic safety data in chronic non-orphan use remain limited.1

What is the FDA and WADA status in 2026?

Forzinity (elamipretide hydrochloride injection, NDA 215244, Stealth BioTherapeutics) was approved under accelerated approval on September 19, 2025 to improve muscle strength in Barth syndrome patients weighing at least 30 kg, based on the intermediate endpoint of knee-extensor strength; continued approval may require a confirmatory trial.45 It carried FDA orphan-drug, priority-review and rare-pediatric-disease designations plus EMA orphan designation.6 All non-Barth uses are unapproved and investigational. 'Research-chemical SS-31,' widely sold 'for research use only — not for human consumption,' is not pharmaceutical-grade and is not the approved Forzinity drug; marketing such material for human use violates federal law on distribution of unapproved new drugs.18

For athletes the picture is less clear-cut than with many banned peptides. Elamipretide is not explicitly named on the 2026 WADA Prohibited List.16 However, WADA category S0 (non-approved substances) captures any pharmacological substance not currently approved for human therapeutic use, so 'research-use-only' peptide forms would plausibly fall under S0, and athletes are under strict liability.17 A diagnosed Barth-syndrome athlete could pursue a Therapeutic Use Exemption for the approved drug, but every athlete should verify status with their national anti-doping organization before use.17

Bottom line. Elamipretide is a cautionary tale about translating mechanism into outcomes. The cardiolipin-binding mechanism is well-characterized and biologically compelling, and the safety profile is benign — but across four large randomized trials it missed every primary clinical endpoint, salvaging only secondary and subgroup signals. Its single approval, Barth syndrome, rests on an intermediate strength endpoint in about 12 patients via accelerated approval, with clinical benefit still to be confirmed. Outside Barth syndrome it remains investigational and is not validated for human enhancement use; longevity and anti-aging claims have no human RCT support. Regulatory facts here are current as of June 2026 and should be re-verified, particularly the NuPOWER and ReNEW confirmatory programs and the status of the Barth accelerated approval.